EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review

Riccardo De Carli, Viviana Minichini, Laetitia Lebrun, An Van Damme iD, Christophe Chantrain, Anais Fohn iD, Sandra Jacobs iD, Frederik De Smet iD, Pierre Leblond iD, Nicolas André iD, Pierluigi Calò iD

Cancers · 08.02.2026 · 18 (4) · 549

DOI: 10.3390/cancers18040549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.02.2026. Verfasst von Riccardo De Carli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Haematology and Oncology, Queen Fabiola Children Hospital, University Hospital of Brussels, 1020 Brussels, Belgium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Yvonne Boël Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse leptomeningeal glioneuronal tumors (DLGNT) are rare pediatric central nervous system tumors, first recognized in the 2016 WHO classification. Their clinical course is highly heterogeneous, and no international consensus treatment guidelines are currently available. This study aims to describe clinical characteristics, disease evolution, and management strategies for pediatric DLGNT patients, with a focus on aggressive forms.

Methods

This retrospective, multicenter, international study (Belgium and France) included pediatric patients diagnosed with DLGNT between 1 February 2016 and 31 December 2024. Clinical, radiological, histopathological, molecular, and therapeutic data were collected. Findings were analyzed and contextualized through an extensive literature review.

Results

Eleven patients were enrolled (median age: 8.2 years; median follow-up: 52 months). The median delay between the first MRI and definitive diagnosis was 6.5 months. Symptoms of intracranially elevated pressure were present in 55% of patients. Two-thirds of the patients presented with leptomeningeal dissemination at diagnosis. The primary tumor site could not be identified in two patients. A KIAA1549::BRAF transcript fusion was detected in 82% of cases, and chromosome 1q gain in 38%. All patients underwent surgery at diagnosis. The median number of therapeutic lines was four: 82% received chemotherapy (weekly vinblastine in 55%, vincristine/carboplatin regimen in 45%), 64% received MAPK pathway-targeted therapy, and 18% underwent radiotherapy. Five-year overall survival (OS) was 68.5%, and median progression-free survival (PFS) was 5.3 months after first-line therapy and 16.5 months after the second line. At the end of follow-up, only one patient achieved complete remission, and 78% of survivors presented with persistent neurological deficits.

Conclusions

This study underscores the significant diagnostic delay, clinical heterogeneity, and absence of standardized therapeutic approaches in pediatric DLGNT patients. Conventional low-grade glioma chemotherapy constitutes the current treatment backbone, while MAPK pathway-targeted therapies show promising potential. Further studies and the establishment of an international registry are crucial to better characterize aggressive subtypes and optimize management strategies.

Schlagwörter

Stichwörter der Autor:innen

DLGNTKIAA1549::BRAF fusionMAPK pathwaydiffuse leptomeningeal glioneuronal tumorslow-grade gliomatovorafenib

Autor:innen und Institutionen

  • Department of Pediatric Haematology and Oncology, Queen Fabiola Children Hospital, University Hospital of Brussels, 1020 Brussels, Belgium.
  • Service d'Hématologie et Oncologie Pédiatrique, University Hospital Timone, Assistance Publique-Hôpitaux de Marseille, 13385 Marseille, France.
  • Pediatric Hematology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, 75019 Paris, France.
  • Department of Neurosurgery, Erasme Hospital, University Hospital of Brussels, 1070 Brussels, Belgium.
  • Department of Pathology, Erasme Hospital, University Hospital of Brussels, 1070 Brussels, Belgium.
  • Department of Pediatric Haematology and Oncology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.

ORCID-Profile: An Van Damme, Anais Fohn, Sandra Jacobs, Frederik De Smet, Pierre Leblond, Nicolas André, Pierluigi Calò

Förderung

  • European Union
  • Yvonne Boël Fund

Zitieren

APA

De Carli, R., Minichini, V., Lebrun, L., Van Damme, A., Chantrain, C., Fohn, A., Jacobs, S., De Smet, F., Leblond, P., André, N., & Calò, P. (2026). From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review. Cancers, 18(4), 549. https://doi.org/10.3390/cancers18040549

Vancouver

De Carli R, Minichini V, Lebrun L, Van Damme A, Chantrain C, Fohn A, et al. From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review. Cancers. 2026;18(4):549. doi:10.3390/cancers18040549

BibTeX
@article{DeCarli2026,
  author = {De Carli, Riccardo and Minichini, Viviana and Lebrun, Laetitia and Van Damme, An and Chantrain, Christophe and Fohn, Anais and Jacobs, Sandra and De Smet, Frederik and Leblond, Pierre and André, Nicolas and Calò, Pierluigi},
  title = {From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {549},
  doi = {10.3390/cancers18040549}
}
Kostenlos starten →